BioArctic
Stock
Stock
ISIN: SE0010323311
Ticker: BIOA B
SE0010323311
BIOA B
Price
Price
CHART BY
Frequently asked questions
What is BioArctic's market capitalization?
The market capitalization of BioArctic is $2.89B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is BioArctic's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for BioArctic is 25.62. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for BioArctic?
BioArctic's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.275. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BioArctic's stock?
Currently, 5 analysts cover BioArctic's stock, with a consensus target price of $28.16. Analyst ratings provide insights into the stock's expected performance.
What is BioArctic's revenue over the trailing twelve months?
Over the trailing twelve months, BioArctic reported a revenue of $196.56M.
How many employees does BioArctic have, and what sector and industry does it belong to?
BioArctic employs approximately 107 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of BioArctic's shares?
The free float of BioArctic is 36.90M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.89B
- EPS (TTM)
- $1.275
- Free Float
- 36.90M
- P/E ratio (TTM)
- 25.62
- Revenue (TTM)
- $196.56M
Pricing
- 1D span
- $30.63$32.62
- 52W span
- $12.73$32.51
Analyst Ratings
The price target is $28.16 and the stock is covered by 5 analysts.
Buy
4
Hold
1
Sell
0
Information
BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. Its research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. The company was founded by Lars Gunnar Lannfelt and Pär Lars Gellerfors in 2003 and is headquartered in Stockholm, Sweden.
- Employees
- 107
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- SE0010323311
- Primary Ticker
- BIOA B
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet